GH Research PLC Ordinary Shares (GHRS) Stock Price
GHRSStock
$28.92+114.83%52W
Market Cap$1.99B
P/E—
PEG Ratio—
Div yield—
Beta1.36
GHRS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)63.29%
Price vs S&P 500 (4W)-2.55%
VGM Score72.55
GHRS Earnings Surprise History
Q2 25-0.15est. -0.20
Q3 25-0.23est. -0.23
Q4 25-0.22est. -0.27
Q1 26-0.31est. -0.26
Q2 26-0.23est. -0.30
GHRS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.20
4.25
4.24
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GHRSGH Research PLC Ordinary Shares | — | — | B | $28.92 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About GH Research PLC Ordinary Shares
GH Research PLC is a clinical-stage biopharmaceutical company developing novel mebufotenin-based therapies for treatment-resistant depression. The company's pipeline includes two proprietary candidates: GH001, an inhalable formulation, and GH002, an intravenous formulation. GH Research is focused on addressing a significant unmet medical need in depression treatment through its dedicated R&D operations.